E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic colorectal cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer in the large inestine that have spread to other parts of the body. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective Dose Escalation Phase:
To characterize the prevalence, severity, drug-relatedness and seriousness of adverse events of PledOx in two doses
Primary Objective Randomised Treatment Phase:
Assess the efficacy of two different doses of PledOx when added to FOLFOX6 chemotherapy as measured by protection from FOLFOX6 toxicity on neutropenia grade 3 or 4 (NCI-CTCAE v4)
|
|
E.2.2 | Secondary objectives of the trial |
To assess PledOx effect on febrile neutropenia
Assessment of anti-tumour effect of PledOx when added to FOLFOX6 chemotherapy evaluated according to RECIST criteria 1.1
To assess PledOx effect on peripheral neuropathy
To assess PledOx effect on oral mucositis
To assess PledOx effects on other DLT
To assess PledOx effect on FOLFOX6 delivered dose and dose intensity
To assess PledOx effect on overall survival (OS)
PledOx effect on Quality of Life (QoL)
Characterize the pharmacokinetic (PK) profile of PledOx (and metabolites ZnDPDP, ZnPLED, ZnDPMP) as well as the metals manganese and zinc
Safety Objectives:
Safety profile of the combination of PledOx when added to FOLFOX6 chemotherapy |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Both the Dose Escalation Phase (Part 1) and Randomised Treatment Phase (Part 2) are described in the same protocol. |
|
E.3 | Principal inclusion criteria |
1.Advanced metastatic colorectal (stage IV) cancer verified by biopsy
2.Patients may have received up to three previous treatment lines of chemotherapy, which may include fluoropyrimidine, irinotecan and targeted therapies. The last dose of antitumor drug must be given at least 4 weeks prior to inclusion and all toxicity (except alopecia and fatigue) resolved. Patients may also be chemotherapy-naïve, have received prior adjuvant treatment but no previous treatment with oxaliplatin
3.CT-scan or MRI of thorax, abdomen and pelvis; within ≤4 weeks before start of chemotherapy
4.Evaluable disease and one measurable site of disease according to RECIST 1.1 criteria (at least 10 mm for CT-scan or MRI)
5.Neurological examination with no significant pathological findings
6.≥18 years
7.WHO performance status 0≤2 and Life expectancy ≥ 3 months
8.Adequate haematological function, Hb ≥ 100 g/L, ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L
9.Adequate renal and hepatic functions: creatinine clearance >50 cc/min, total bilirubin ≤ 1.5 times ULN, ASAT and ALAT ≤ 3 times ULN (ASAT and ALAT ≤ 5 times ULN in case of liver metastases)
10.INR ≤1.5 times ULN, unless receiving therapeutic anticoagulation
11.Negative pregnancy test for females of child-producing potential
12.Written informed consent given |
|
E.4 | Principal exclusion criteria |
1.Tumours other than colorectal adenocarcinomas (within the previous 5 years) except for curatively treated non melanoma skin cancer or in situ carcinoma of the cervix
2.Evidence of central nervous system metastases
3.Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn’s disease or ulcerative colitis
4.History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure, myocardial infarction or unstable angina in the past six (6) months prior to Day 1 of treatment and serious arrhythmias requiring medication for treatment
5.Prolonged QTC interval >450 msec
6.Known history of stroke or cerebrovascular accident in the past six (6) months
7.Severe diarrhoea
8.Chronic infection or uncontrolled serious illness causing immunodeficiency
9.Any uncontrolled serious illness or medical condition
10.Received mangafodipir at any time
11.Welders, mine workers or other workers in occupations (current or past) where high manganese exposure is likely
12.Pre-existing neurodegenerative disease (Parkinson’s, Alzheimer’s, Huntington’s etc.) or neuromuscular disorder (Multiple sclerosis, Amyotrophic lateral sclerosis, Polio, hereditary neuromuscular disease)
13.Major psychiatric disorder (major depression, psychosis)
14.Participation in another clinical study with an investigational medicinal product within 1 month prior to inclusion.
15. Blood manganese concentration values >18,3 µg/L at screening |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Neutropenia grade 3 and 4 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At the end of treatment phase. |
|
E.5.2 | Secondary end point(s) |
• Febrile neutropenia
• CT or MRI of thorax, abdomen and pelvis will be used to identify and characterize target and non-target lesions, according to the RECIST 1.1. (CR, PR, SD or PD) at baseline and during treatment until progression of the disease or up to 12 months after end of investigational medicinal product (IMP) administration:
o Response rate (RR)
o Progression free survival (PFS)
• Symptoms and signs of peripheral neuropathy
o Presence of positive cold
o Patient reported outcome: Oxaliplatin-associated sensory neuropathy scale (Leonard et al.)
o Physician observed neuropathy: NCI-CTCAE v4 and Oxaliplatin Sanofi Specific Scale
• Oral mucositis
• Absolute neutrophil count and other relevant laboratory test variables
• Neutropenia grade
• Dose change (dose frequency and intensity)
• Overall survival
• QoL
• Pharmacokinetic variables:
o Plasma concentration half-life, t½.
o The maximum observed plasma concentration, Cmax, and the corresponding time, tmax.
o The area under the plasma concentration-time curve from time 0 to last observed concentration, AUCt.
o The area under the plasma concentration-time curve from time 0 to infinity, AUC0-
SAFETY ENDPOINTS:
Safety parameters; Adverse drug reactions and serious adverse drug reactions, changes in haematology and chemistry values, including those associated with hepatic and renal function, and assessment of physical examinations, vital signs and cardiac function (QT prolongation).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12 months after end of treatment except for overal survival which is 20 months after end of treatment.
Safety end points will be evaluated continouosly. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Part 1 is Open and Part 2 is double blind. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
Denmark |
Georgia |
Germany |
Portugal |
Serbia |
Sweden |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of Trial is defined as last visit of the last patient (12 months after End of Treatment).
In addition, all subjects will be followed for overall survival for 8 months after End of Trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |